Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes
- 1 August 1987
- journal article
- research article
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 89 (03) , 301-306
- https://doi.org/10.1055/s-0029-1210654
Abstract
Human recombinant interleukin-2 (IL-2) was labelled with Iodine-123 using modified Bolton and Hunter method. Separation from free iodine was performed by gel filtration chromatography using a Sephadex G10 column. HPLC analysis of labelled IL-2 showed that 98% of TCA precipitable radioactivity eluted in a single peak. The immunoreactivity of 123I-labelled IL-2 was determined by divert binding using the Fluorescence Activated Cell Sorter (FACS) and by receptor binding assay of IL-2 to activated lymphocytes. To demonstrate in vivo binding to activated lymphocytes, 123I-labelled IL-2 was injected intravenously into a newly diagnosed diabetic BB/Wistar rat. Higher radioactivity was detected in the pancreas and in the lymph nodes of the BB/W rat compared to a normal rat. These preliminary data show that 123I-labelled IL-2 retains its immunoreactivity and capacity to bind to activated lymphocytes both in vitro and in vivo and may be used for in vivo localization of lymphocytic infiltration in Type 1 diabetes.Keywords
This publication has 0 references indexed in Scilit: